Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of MK-4646 With BIC/FTC/TAF and DTG
NCT07532304Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of MK-4646 in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity. Started May 2026; status: completed.
02
Drugs
MK-4646
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07532304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07532304.